Last $1.31 USD
Change Today 0.00 / 0.00%
Volume 41.3K
KOOL On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

cesca therapeutics inc (KOOL) Snapshot

Open
$1.33
Previous Close
$1.31
Day High
$1.33
Day Low
$1.29
52 Week High
01/22/14 - $3.24
52 Week Low
11/25/13 - $0.71
Market Cap
52.6M
Average Volume 10 Days
63.3K
EPS TTM
$-0.42
Shares Outstanding
40.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CESCA THERAPEUTICS INC (KOOL)

cesca therapeutics inc (KOOL) Related Bloomberg News

View More Bloomberg News

cesca therapeutics inc (KOOL) Related Businessweek News

No Related Businessweek News Found

cesca therapeutics inc (KOOL) Details

Cesca Therapeutics Inc., an autologous cell-based regenerative medicine company, researches, develops, and commercializes autologous cell-based therapeutics for use in regenerative medicine. The company develops and manufactures automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products. Its products include SurgWerks Platform, proprietary stem cell therapy point-of-care kit systems for treating vascular and orthopedic indications, which integrates various indication specific systems, such as cell harvesting, cell processing and selection, cell diagnostics, and cell delivery; and CellWerks Platform, a proprietary stem cell laboratory kit for processing target cells used in the treatments of oncological and hematological disorders. The company also offers AXP AutoXpress Platform (AXP), a proprietary family of automated devices that includes the AXP and the MXP MarrowXpress and companion sterile blood processing disposables for harvesting stem cells in closed systems; and MarrowXpress Platform (MXP), a derivative product of the AXP and its accompanying disposable bag set, which isolates and concentrates stem cells from bone marrow. In addition, its products consist of the Res-Q 60 (Res-Q), a point-of-care system designed for the preparation of cell concentrates, including stem cells, from bone marrow aspirates and whole blood for platelet rich plasma; and the BioArchive System, an automated cryogenic device, used by cord blood stem cell banks in approximately 30 countries for cryopreserving and archiving cord blood stem cell units for transplant. The company was formerly known as ThermoGenesis Corp. and changed its name to Cesca Therapeutics Inc. in February 2014. The company was founded in 1986 and is headquartered in Rancho Cordova, California.

66 Employees
Last Reported Date: 12/24/13
Founded in 1986

cesca therapeutics inc (KOOL) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $315.0K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $61.0K
Vice President of Corporate Development & Sci...
Total Annual Compensation: $240.0K
Vice President of Manufacturing, Engineering ...
Total Annual Compensation: $270.0K
Compensation as of Fiscal Year 2013.

cesca therapeutics inc (KOOL) Key Developments

Cesca Therapeutics Inc. Presents at Aegis Capital 2014 Healthcare & Technology Conference, Sep-12-2014 11:25 AM

Cesca Therapeutics Inc. Presents at Aegis Capital 2014 Healthcare & Technology Conference, Sep-12-2014 11:25 AM. Venue: The Encore at Wynn Las Vegas, 3121 Las Vegas Blvd. South, Las Vegas, NV 89109, United States. Speakers: Matthew T. Plavan, Chief Executive Officer and Director.

Cesca Therapeutics and Fortis Healthcare Limited Announce Master Collaboration Agreement

Cesca Therapeutics and Fortis Healthcare Limited announced a master collaboration agreement that extends their important existing relationship. The agreement affirms Cesca's cellular therapy and cord blood bank at the Fortis Hospital Memorial Research Institute (FMRI) in Gurgaon, renews the cord blood banking collaboration and launches the stem cell therapy services for hematological diseases across the Fortis network. The scope of services now provide for specific regenerative medicine programs including: cord blood banking services, point of care autologous cell therapy product and services, hematopoietic stem cell therapy services (i.e. both autologous and allogeneic bone marrow transplant) and oncological cellular therapy services. Fortis Healthcare and Cesca Therapeutics will continue to leverage Fortis' hospital network and respective areas of clinical expertise to launch world-class matched and unmatched bone marrow transplants and create more awareness around the benefits of stem cell therapy across India.

Cesca Therapeutics Inc. Presents at Rodman & Renshaw 16th Annual Global Investment Conference, Sep-09-2014 01:40 PM

Cesca Therapeutics Inc. Presents at Rodman & Renshaw 16th Annual Global Investment Conference, Sep-09-2014 01:40 PM. Venue: New York Palace Hotel – 455 Madison Avenue, New York, NY 10022, United States. Speakers: Matthew T. Plavan, Chief Executive Officer and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KOOL:US $1.31 USD 0.00

KOOL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Chart Industries Inc $62.38 USD -2.30
County Line Energy Corp $0.0035 USD 0.00
Cytomedix Inc $0.44 USD 0.00
Pall Corp $83.88 USD -0.17
View Industry Companies
 

Industry Analysis

KOOL

Industry Average

Valuation KOOL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.3x
Price/Book 1.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CESCA THERAPEUTICS INC, please visit www.cescatherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.